Sequoia Capital

Myome helps identify genes that cause disease and act based on leading science. The data is secure, portable, and reusable throughout life.

Kenko Health is a healthcare financing provider that offers comprehensive individual healthcare plans designed to manage medical expenses effectively. The company focuses on affordable monthly premiums, allowing customers to access a range of services, including discounts on medications, doctor fees, lab tests, mental health services, dental care, and outpatient hospital bills. By aiming to establish a health management organization, Kenko Health seeks to enhance medical coverage for its customers, ensuring they receive necessary care without incurring prohibitive costs.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

VIRTUE Diagnostics(Suzhou)Co.,Ltd. develops in vitro diagnostic platform. The company offers technology platforms including clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. VIRTUE Diagnostics(Suzhou)Co.,Ltd. was founded in 2019 and is based in Suzhou, China with a research and development office in Singapore.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies.

WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical and health technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing solutions that utilize medical cloud and artificial intelligence technologies for various stakeholders, including governments, hospitals, and primary medical institutions. WeDoctor offers a range of services through its WeDoctor Cloud platform, which facilitates online and offline medical services, general practice, specialty consultations, and appointment registrations. Additionally, the company provides managed health services through WeDoctor HMO, aiming to enhance the medical care experience for users. With a mission to improve access to healthcare and promote overall wellness, WeDoctor strives to empower individuals and families through innovative healthcare solutions that integrate both digital and traditional services.

D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

Healthlane is a healthcare technology company that operates an online application aimed at enhancing access to quality and affordable healthcare services in Africa. Established in 2020 and headquartered in Lagos, Nigeria, with additional offices in Yaounde, Cameroon, and San Francisco, California, the platform facilitates users in tracking medical appointments and consolidating their health data. It offers features such as virtual medical advice on various health topics, including pregnancy, vaccinations, lab results, family planning, and insurance records. By enabling direct communication with certified doctors, Healthlane empowers individuals to make informed health decisions and efficiently monitor their health status.

MedGenome Labs Private Ltd. is a molecular genetic diagnostics company based in Chennai, India, focused on personalized healthcare through advanced sequencing technologies. The company specializes in Sanger sequencing and next-generation sequencing, offering a variety of diagnostic tests, including exome, whole genome, and mitochondrial genome sequencing. MedGenome provides comprehensive disease panels, such as hereditary cancer panels for mutations linked to various cancer syndromes, tumor somatic mutation panels for detecting DNA alterations in tumors, and genetic tests for cardiac, eye, and neuromuscular diseases. Additionally, it offers targeted panels for genetic mutations related to non-syndromic deafness and autism. MedGenome also features OncoMD, a database of cancer-related mutations derived from peer-reviewed sequencing studies. Through these molecular diagnostic tests, MedGenome assists clinicians in identifying gene variations relevant to treatment options and disease risk assessment. The company has strategic collaborations, including one with Denali Therapeutics, and was incorporated in 2013 as a subsidiary of SciGenom Labs Pvt Ltd.

Developer of dental imaging technology and dental clinic management software. The company's software helps dental professionals accurately diagnose patient conditions through oral CT scanning, as well as keep track of patient records and appointments, enabling dental professionals to provide treatment more efficiently.

Phrase Health, Inc. is a Philadelphia-based company founded in 2018 that specializes in software solutions for the healthcare sector. The company focuses on helping hospitals monitor and analyze the information available to doctors and nurses at the point of care, thereby enhancing the quality of care delivered to patients. Through its innovative technology, Phrase Health aims to streamline communication and improve clinical decision-making in healthcare settings.

Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.

Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.

MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.

OncoStem Diagnostics Pvt. Ltd. is a Bengaluru-based company established in 2011 that specializes in the research and development of cancer diagnostic tests aimed at predicting the risk of cancer recurrence. The company addresses a critical need in oncology, as the recurrence of cancer remains a significant concern for both patients and healthcare providers, often leading to increased morbidity and mortality. OncoStem focuses on creating novel diagnostic tests that integrate the molecular signature of cancer with established clinic-pathological parameters to enhance prognostic evaluations. This approach allows physicians to tailor treatment plans more effectively, potentially incorporating targeted therapies to reduce the side effects associated with conventional treatments like chemotherapy and radiation. Initially, OncoStem is concentrating on breast cancer, seeking to improve patient outcomes through precise risk assessment and targeted drug recommendations.

Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.

MedGenome Labs Private Ltd. is a molecular genetic diagnostics company based in Chennai, India, focused on personalized healthcare through advanced sequencing technologies. The company specializes in Sanger sequencing and next-generation sequencing, offering a variety of diagnostic tests, including exome, whole genome, and mitochondrial genome sequencing. MedGenome provides comprehensive disease panels, such as hereditary cancer panels for mutations linked to various cancer syndromes, tumor somatic mutation panels for detecting DNA alterations in tumors, and genetic tests for cardiac, eye, and neuromuscular diseases. Additionally, it offers targeted panels for genetic mutations related to non-syndromic deafness and autism. MedGenome also features OncoMD, a database of cancer-related mutations derived from peer-reviewed sequencing studies. Through these molecular diagnostic tests, MedGenome assists clinicians in identifying gene variations relevant to treatment options and disease risk assessment. The company has strategic collaborations, including one with Denali Therapeutics, and was incorporated in 2013 as a subsidiary of SciGenom Labs Pvt Ltd.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

HealthEngine Pty Ltd operates an online healthcare destination in Australia. The company offers an online booking system that allows patients to find, book, and manage their appointments online; an online health directory that list medical practices in various categories, including GP, dentist, physio, chiropractor, psychologist, and more; HealthEngine recalls, a solution to centralize and manage various recalls; and a website for medical practices. HealthEngine Pty Ltd was founded in 2006 and is based in Perth, Australia.

Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.

Suburban Diagnostics (India) Private Limited owns, operates, and franchises diagnostic centers in India. It offers services in the areas of pathology, digital X-ray, sonography, ECG, stress tests, color Doppler, 2D echo, preventive health management programs, mammography, and OPG. The company also provides corporate health care services, such as pre-employment check ups, annual health check ups, and wellness and lifestyle management programs. In addition, it offers pre-insurance medical check ups, including blood tests, urine tests, TMT, medical examinations, and pulmonary function tests. Further, the company provides medical tourism, clinical trials, and home services. It serves insurance companies, third party administrators, and corporate clients. Suburban Diagnostics (India) Private Limited was founded in 1994 and is based in Mumbai, India.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.

MedGenome Labs Private Ltd. is a molecular genetic diagnostics company based in Chennai, India, focused on personalized healthcare through advanced sequencing technologies. The company specializes in Sanger sequencing and next-generation sequencing, offering a variety of diagnostic tests, including exome, whole genome, and mitochondrial genome sequencing. MedGenome provides comprehensive disease panels, such as hereditary cancer panels for mutations linked to various cancer syndromes, tumor somatic mutation panels for detecting DNA alterations in tumors, and genetic tests for cardiac, eye, and neuromuscular diseases. Additionally, it offers targeted panels for genetic mutations related to non-syndromic deafness and autism. MedGenome also features OncoMD, a database of cancer-related mutations derived from peer-reviewed sequencing studies. Through these molecular diagnostic tests, MedGenome assists clinicians in identifying gene variations relevant to treatment options and disease risk assessment. The company has strategic collaborations, including one with Denali Therapeutics, and was incorporated in 2013 as a subsidiary of SciGenom Labs Pvt Ltd.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Suburban Diagnostics (India) Private Limited owns, operates, and franchises diagnostic centers in India. It offers services in the areas of pathology, digital X-ray, sonography, ECG, stress tests, color Doppler, 2D echo, preventive health management programs, mammography, and OPG. The company also provides corporate health care services, such as pre-employment check ups, annual health check ups, and wellness and lifestyle management programs. In addition, it offers pre-insurance medical check ups, including blood tests, urine tests, TMT, medical examinations, and pulmonary function tests. Further, the company provides medical tourism, clinical trials, and home services. It serves insurance companies, third party administrators, and corporate clients. Suburban Diagnostics (India) Private Limited was founded in 1994 and is based in Mumbai, India.

Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Yicheng Bioelectronics Technology is a Chinese enterprise focused on the manufacture of rapid medical detection solutions. Founded in 1993, Beijing Yicheng’s product lineup include glucometers, whole blood lactate analyzers, whole blood ketone body analyzers, whole blood cholesterol analyzers, renal damage detection cards, microchip systems for glycosylated hemoglobin, albumin antibodies with detection kits, hemoglobin antibodies with detection kits, glycosylated hemoglobin antibodies with detection kits, and more.

eCardio Diagnostics provides remote cardiac monitoring products and services that improve the flexibility, speed and accuracy of arrhythmia diagnosis. Headquartered in Houston, Texas, eCardio has served thousands of physicians and patients suffering from heart rhythm disorders since 2004. eCardio is an important partner in the delivery of optimal patient care. eCardio offers an array of clinical services and leading-edge devices designed to simplify and streamline the process of arrhythmia monitoring. This allows physicians to make more precise diagnoses and enhances the follow-up and management of their patients.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

SCIO Health Analytics provides healthcare analytics solutions and services globally. It provides care optimization, network optimization, reimbursement optimization, risk adjustment, and quality measurement, and integrated data management and insights platforms. The company serves payers, providers, health service companies, and life sciences clients worldwide. SCIOInspire was founded in 2007 and is based in West Hartford, Connecticut with delivery centers in the United States, India, and the United Kingdom.